Viatris | VTRS - Cost Of Sales


Viatris reported $2.3B in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Celltrion KRW 92.83B 14.59B Mar/2026
Cspc Pharmaceutical CNY 2.11B 173.58M Dec/2025
Deva Holding AS TRY 991.13M 182.81M Sep/2023
Divis Laboratories Ltd INR 11.19B 1.2B Jun/2026
Kangmei Pharma CNY 841.45M 271.27M Mar/2026
Knight Therapeutics CAD 82.22M 1.03M Dec/2025
Laboratorios Farma EUR 186.09M 11.06M Dec/2023
Medical Developments International AUD 7.09M 4.91M Dec/2025
Neuren Pharmaceuticals AUD 7.45M 6.56M Jun/2025
Organigram Holdings CAD 43.39M 13.54M Mar/2026
Pharma Mar EUR 4.73M 1.08M Jun/2026
Qiagen NV USD 196.45M 13.73M Jun/2026
Sartorius EUR 478.7M 5.9M Jun/2026
Sino Biopharmaceutical CNY 3.08B 589.65M Jun/2025
Tilray USD 164.37M 8.41M Sep/2025
Viatris USD 2.3B 59.5M Jun/2026
Zealand Pharma A/S 410K 5K Jun/2025
Zz Pientze Pharmaceu CNY 1.17B 418.33M Jun/2026